Cannabinoid Education 360 is an educational initiative that delivers easily accessible, evidence-based, balanced information on cannabinoids and cannabis-based medicines and products, for healthcare professionals and non-healthcare professionals.
Our ambition is to provide a full 360-degree perspective on what is really known about the science of cannabinoids, the research behind cannabis-based medicines, and the laws and policy frameworks that regulate them. We want to help dispel any myths and provide clarity around this important, yet complex field of medicine. Visit the Cannabinoid Education 360 website to learn more.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. We are identifying new options for patients by actively exploring small molecules, biologics, innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries.
Date of preparation: February 2022